Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
<p>Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.</p>
-д хадгалсан:
| Үндсэн зохиолч: | Seyed Reza Mousavi (13223324) (author) |
|---|---|
| Бусад зохиолчид: | Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author) |
| Хэвлэсэн: |
2025
|
| Нөхцлүүд: | |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
-н: Seyed Reza Mousavi (13223324)
Хэвлэсэн: (2025) -
The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
-н: Seyed Reza Mousavi (13223324)
Хэвлэсэн: (2025) -
Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
-н: Seyed Reza Mousavi (13223324)
Хэвлэсэн: (2025) -
Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
-н: Seyed Reza Mousavi (13223324)
Хэвлэсэн: (2025) -
Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
-н: Anna Starshinova (22571846)
Хэвлэсэн: (2025)